^
Association details:
| Biomarker: | BTLA elevation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Serum levels of soluble B and T lymphocyte attenuator (sBTLA) predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies
Published date:
04/22/2021
Excerpt:
Serum levels of sBTLA were analyzed by multiplex immunoassay in n=84 patients receiving ICI therapy for solid malignancies...patients with initial sBTLA levels above the calculated prognostic cut-off value (311.64 pg/ml) had a median OS of only 138 days compared to 526 for patients with sBTLA levels below this value (p=0.001).....circulating sBTLA could represent a non-invasive biomarker to predict outcome to ICI therapy, helping to select eligible therapy candidates.
DOI:
https://doi.org/10.1002/ijc.33610